University of SaskatchewanHARVEST
  • Login
  • Submit Your Work
  • About
    • About HARVEST
    • Guidelines
    • Browse
      • All of HARVEST
      • Communities & Collections
      • By Issue Date
      • Authors
      • Titles
      • Subjects
      • This Collection
      • By Issue Date
      • Authors
      • Titles
      • Subjects
    • My Account
      • Login
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      View Item 
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item

      Application of a new small RNA molecule, RNA-LZ-1, as a vaccine adjuvant

      Thumbnail
      View/Open
      LANGTON-THESIS-2017.pdf (1.346Mb)
      Date
      2017-09-18
      Author
      Langton, Magda T 1992-
      ORCID
      0000-0003-1837-0889
      Type
      Thesis
      Degree Level
      Masters
      Metadata
      Show full item record
      Abstract
      Influenza A viruses are important pathogens that cause disease in a wide variety of species leading to economic losses and added burden on health care. Recently, outbreaks of avian influenza viruses in the human population have added to this growing risk of pandemic influenza viruses. Therefore, strategies to address the demands of higher efficiency, immunogenicity, and safety in influenza vaccines must be explored. One strategy which addresses efficiency and immunogenicity is to explore the addition of an adjuvant to influenza vaccines. Adjuvants are commonly used vaccine components which are included to induce a robust immune response leading to antigen sparing, a broader spectrum of protection and the elimination of a booster. Recently the retinoic acid-inducible gene-I (RIG-I) pathway, which is the natural defense against RNA viruses, has become an attractive target for adjuvant development. In this thesis, we sought to explore the possibility of a small RNA molecule, RNA- LZ-1, identified in our laboratory as a RIG-I agonist as an adjuvant. This project evaluated the induction of pro-inflammatory cytokines, chemokines, and interferons by RNA-LZ-1 in vitro and in vivo, and tested its ability to induce antigen-specific antibodies when paired with H5N1 and H7N9 inactivated whole influenza viruses. We hypothesized that due to RNA-LZ-1’s binding affinity for RIG-I it will induce a broad spectrum immune response and fortified adaptive response when used as an adjuvant. Overall our results showed that RNA-LZ-1 was capable of inducing activation of a diverse spectrum of inflammatory genes and proteins in vitro and in vivo. In human macrophages and lung epithelial cells RNA-LZ-1 induced significant levels of IFN-β protein and mRNA fold change. We also showed that as early as 3 hours post-injection, RNA-LZ-1 was capable of up-regulating immune genes with the effect dissipating by 48 hours post-injection. These immune genes were grouped as follows cytokines (IL-12α, IL-12β, IL-6, and IL-18), chemokines (MIP-1α, RANTES, MIP-2, MCP-1, and IP-10), and interferons (IFN-α, IFN-β, and IFN-ɣ). The overall immune response observed was skewed towards a Th1 response. In vivo, RNA-LZ-1 was able to induce protective antigen-specific antibodies against H5N1 in comparable levels to the proven VIDO triple adjuvant showing that RNA-LZ-1 is a strong candidate as an adjuvant for influenza vaccines.
      Degree
      Master of Science (M.Sc.)
      Department
      School of Public Health
      Program
      Vaccinology and Immunotherapeutics
      Supervisor
      Zhou, Yan
      Committee
      Tikoo, Suresh; Wilson, Heather; Badea, Ildiko
      Copyright Date
      August 2017
      URI
      http://hdl.handle.net/10388/8104
      Subject
      adjuvant, vaccine
      Collections
      • Graduate Theses and Dissertations
      University of Saskatchewan

      University Library

      © University of Saskatchewan
      Contact Us | Disclaimer | Privacy